Activated PI3Kdelta Syndrome (APDS); PASLI Disease
An Open-label, Non-randomized Extension Study to Evaluate the Long Term Safety, Tolerability, Efficacy and Pharmacokinetics of CDZ173 in Patients With APDS/PASLI (Activated Phosphoinositide 3-kinase Delta Syndrome/p110δ-activating Mutation Causing Senescent T Cells, Lymphadenopathy and Immunodeficiency)
ClinicalTrials.gov ID: NCT02859727 | Gender: All | Age(s): 12 Years to 75 Years (Child, Adult, Older Adult) | Drug: CDZ173
Ankylosing Spondylitis
A Randomized, Double-blind, Parallel-group, Multicenter Study of Secukinumab to Compare 300 mg and 150 mg at Week 52 in Patients With Ankylosing Spondylitis Who Are Randomized to Dose Escalation After Not Achieving Inactive Disease During an Initial 16 Weeks of Open-label Treatment With Secukinumab 150 mg (ASLeap)
ClinicalTrials.gov ID: NCT03350815 | Gender: All | Age(s): 18 Years and older (Adult, Older Adult) | Drug: 150 mg open-label secukinumab, 150 mg double-blinded secukinumab & 3300 mg double-blinded secukinumab
Ankylosing Spondylitis or Non-radiographic Axial Spondyloarthritis
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Multicenter Study of Intravenous Secukinumab to Compare Efficacy at 16 Weeks With Placebo and to Assess Safety and Tolerability up to 52 Weeks in Subjects With Active Ankylosing Spondylitis or Non-radiographic Axial SpondyloArthritis
ClinicalTrials.gov ID: NCT04156620 | Gender: All | Age(s): 18 Years and older (Adult, Older Adult) | Drug: Secukinumab & Placebo
Arthritis, Psoriatic
A 52-week, Multicenter Study to Assess the Time Course of Response to Secukinumab on Joint Inflammation Using Power Doppler Ultrasonography in Patients With Active Psoriatic Arthritis
ClinicalTrials.gov ID: NCT02662985 | Gender: All | Age(s): 18 Years and older (Adult, Older Adult) | Drug: AIN457 (secukinumab) & Placebo
Atopic Dermatitis
A Randomized, Double Blind, Multicenter Extension to CZPL389A2203 Dose-ranging Study to Assess the Short-term and Long-term Safety and Efficacy of Oral ZPL389 With Concomitant Use of TCS and/or TCI in Adult Patients With Atopic Dermatitis.
ClinicalTrials.gov ID: NCT03948334 | Gender: All | Age(s): 18 Years and older (Adult, Older Adult) | Drug: ZPL389 & TCS and/or TCI
Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled Multicenter Dose Ranging Study to Assess the Safety and Efficacy of Multiple Oral ZPL389 Doses in Patients With Moderate to Severe Atopic Dermatitis (ZEST Trial)
ClinicalTrials.gov ID: NCT03517566 | Gender: All | Age(s): 18 Years and older (Adult, Older Adult) | Drug: Placebo & ZPL389
Autoimmune Hepatitis
A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of VAY736 in Autoimmune Hepatitis
ClinicalTrials.gov ID: NCT03217422 | Gender: All | Age(s): 18 Years to 75 Years (Adult, Older Adult) | Drug: VAY736 & Other: Placebo
Chronic Spontaneous Urticaria
A Multi-center, Randomized, Double-blind, Active and Placebo-controlled Study to Investigate the Efficacy and Safety of Ligelizumab (QGE031) in the Treatment of Chronic Spontaneous Urticaria (CSU) in Adolescents and Adults Inadequately Controlled With H1-antihistamines
ClinicalTrials.gov ID: NCT03580369 | Gender: All | Age(s): 12 Years and older (Child, Adult, Older Adult) | Drug: Biological: Ligelizumab & Omalizumab & Other: Placebo
Chronic Spontaneous Urticaria
A Multi-center, Randomized, Double-blind, Active and Placebo-controlled Study to Investigate the Efficacy and Safety of Ligelizumab (QGE031) in the Treatment of Chronic Spontaneous Urticaria (CSU) in Adolescents and Adults Inadequately Controlled With H1-antihistamines
ClinicalTrials.gov ID: NCT03580356 | Gender: All | Age(s): 12 Years and older (Child, Adult, Older Adult) | Drug: Biological: Ligelizumab & Omalizumab & Other: Placebo
Chronic Spontaneous Urticaria
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2b Dose-finding Study to Investigate the Efficacy and Safety of Ligelizumab (QGE031) in Adolescent Patients With Chronic Spontaneous Urticaria (CSU)
ClinicalTrials.gov ID: NCT03437278 | Gender: All | Age(s): 12 Years to 18 Years (Child, Adult) | Drug: Ligelizumab & Placebo
Chronic Spontaneous Urticaria
A Multicenter, Randomized, Double-blind, Placebo- Controlled Phase 2b Dose-finding Study to Investigate the Efficacy, Safety and Tolerability of LOU064 in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihistamines
ClinicalTrials.gov ID: NCT03926611 | Gender: All | Age(s): 18 Years to 99 Years (Adult, Older Adult) | Drug: LOU064 Arm 1, LOU064 Arm 2, LOU064 Arm 3, LOU064 Arm 4, LOU064 Arm 5, LOU064 Arm 6 & Placebo arm
Colitis, Ulcerative
A Randomized, Multi-center, Subject and Investigator-blinded, Placebo-controlled, Parallel-group Study to Assess the Efficacy Safety and Tolerability of LYS006 in Patients With Mild to Moderate Ulcerative Colitis
ClinicalTrials.gov ID: NCT04074590 | Gender: All | Age(s): 18 Years to 65 Years (Adult, Older Adult) | Drug: LYS006 & Placebo
Common Variable Immunodeficiency
An Open-label, Non-randomized, Within-patient Dose-finding Study Followed by a Randomized, Subject, Investigator and Sponsor-blinded Placebo Controlled Study to Assess the Efficacy and Safety of CDZ173 in Patients With APDS/PASLI
ClinicalTrials.gov ID: NCT02435173 | Gender: All | Age(s): 12 Years to 75 Years (Child, Adult, Older Adult) | Drug: CDZ173
Hidradenitis Suppurativa
A Randomized, Double-blind, Multi-center Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (SUNSHINE).
ClinicalTrials.gov ID: NCT03713619 | Gender: All | Age(s): 18 Years and older (Adult, Older Adult) | Drug: Secukinumab
Hidradenitis Suppurativa
A Randomized, Double-blind, Multicenter Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (SUNRISE)
ClinicalTrials.gov ID: NCT03713632 | Gender: All | Age(s): 18 Years and older (Adult, Older Adult) | Drug: Secukinumab
Hidradenitis Suppurativa
A Randomized, Subject and Investigator Blinded, Placebo-controlled and Multi-center Platform Study, to Assess Efficacy and Safety of Different Investigational Drugs in Patients With Moderate to Severe Hidradenitis Suppurativa
ClinicalTrials.gov ID: NCT03827798 | Gender: All | Age(s): 18 Years to 65 Years (Adult, Older Adult) | Drug: CFZ533, Placebo to CFZ533, Drug: LYS006 & Placebo to LYS006
Idiopathic Pulmonary Fibrosis
A Subject-, Investigator-, and Sponsor-blinded, Randomized, Placebo-controlled, Multicenter Study to Investigate Efficacy, Safety, and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis
ClinicalTrials.gov ID: NCT03287414 | Gender: All | Age(s): 40 Years to 80 Years (Adult, Older Adult) | Drug: VAY736 & Placebo
Inflammatory Acne
A Randomized, Subject and Investigator Blinded, Placebo Controlled, Multi-center Study in Parallel Groups to Assess the Efficacy and Safety of LYS006 in Patients With Moderate to Severe Inflammatory Acne
ClinicalTrials.gov ID: NCT03497897 | Gender: All | Age(s): 18 Years to 45 Years (Adult) | Drug: LYS006 & Placebo
Kidney Transplant Rejection
A Partially-blinded, Active-controlled, Multicenter, Randomized Study Evaluating Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in de Novo and Maintenance Kidney Transplant Recipients (CIRRUS I)
ClinicalTrials.gov ID: NCT03663335 | Gender: All | Age(s): 18 Years and older (Adult, Older Adult) | Drug: Tacrolimus - MMF - +/- corticosteroids & Biological: CFZ533
Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
NASH EXploratory Single and COmbination Treatment (NEXSCOT): An Open Label, Multicenter, Platform Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Various Single and Combination Treatments in Patients With Non-alcoholic Fatty Liver Disease (NAFLD) Who Manifest a Non-alcoholic Steatohepatitis (NASH)-Like Biomarker Phenotype
ClinicalTrials.gov ID: NCT04147195| Gender: All | Age(s): 18 Years and older (Adult, Older Adult) | Drug: LYS006 & LYS006 + Tropifexor (LJN452)
Non-alcoholic Steatohepatitis (NASH)
A Randomized, Double-blind, Multicenter Study to Assess the Safety, Tolerability, and Efficacy of a Combination Treatment of Tropifexor (LJN452) and Cenicriviroc (CVC) in Adult Patients With Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis
ClinicalTrials.gov ID: NCT03517540 | Gender: All | Age(s): 18 Years and older (Adult, Older Adult) | Drug: Tropifexor (LJN452) & Cenicriviroc (CVC)
Non Alcoholic Steatohepatitis (NASH)
A Randomized, Double-blind, Parallel-group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Oral Tropifexor (LJN452) & Licogliflozin (LIK066) Combination Therapy, Compared to Each Monotherapy, for Treatment of Adult Patients With Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis
ClinicalTrials.gov ID: NCT04065841 | Gender: All | Age(s): 18 Years and older (Adult, Older Adult) | Drug: Tropifexor & Licogliflozin
Osteoarthritis
A Two-part, Randomized, Placebo-controlled, Patient and Investigator Blinded, Study Investigating the Safety, Tolerability and Preliminary Efficacy of Intra-articular LNA043 Injections in Regenerating the Articular Cartilage of the Knee in Patients With Articular Cartilage Lesions (Part A) and in Patients With Knee Osteoarthritis (Part B)
ClinicalTrials.gov ID: NCT03275064 | Gender: All | Age(s): 18 Years to 75 Years (Adult, Older Adult) | Drug: LNA043 & Placebo
Sjögren Syndrome
An Adaptive Phase 2 Randomized Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Multiple LOU064 Doses in Patients With Moderate to Severe Sjögren's Syndrome (LOUiSSe)
ClinicalTrials.gov ID: NCT04035668 | Gender: All | Age(s): 18 Years to 75 Years (Adult, Older Adult) | Drug: LOU064 & Placebo
Sjögren Syndrome
A 48-week, 6-arm, Randomized, Double-blind, Placebo-controlled Multicenter Trial to Assess the Safety and Efficacy of Multiple CFZ533 Doses Administered Subcutaneously in Two Distinct Populations of Patients With Sjögren's Syndrome (TWINSS)
ClinicalTrials.gov ID: NCT03905525 | Gender: All | Age(s): 18 Years and older (Adult, Older Adult) | Drug: CFZ533 & Placebo
